Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Purpose This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) –positive metastatic breast cancer (MBC). Patients and Methods Patients were randomly assigned to six cycles of docetaxel...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Michel Marty, Francesco Cognetti, D Maraninchi, Ray Snyder, L. Mauriac, M. Tubiana-Hulin, Stephen Chan, David Robert Grimes, Antonio Antón, Aña Lluch, John Kennedy, Kenneth J. O’Byrne, Pierfranco Conté, Michael Green, Carol Ward, Karen Mayne, Jean-Marc Extra
Формат: Artigo
Язык:английский
Опубликовано: 2005
Online-ссылка:https://doi.org/10.1200/jco.2005.04.173
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2005.04.173?role=tab
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Internet

https://doi.org/10.1200/jco.2005.04.173
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2005.04.173?role=tab

Схожие документы